BRPI0509732A - pró-fármaco solúvel em água, composição farmacêutica, agente terapêutico, agente antifungo e uso do referido pró-fármaco - Google Patents

pró-fármaco solúvel em água, composição farmacêutica, agente terapêutico, agente antifungo e uso do referido pró-fármaco

Info

Publication number
BRPI0509732A
BRPI0509732A BRPI0509732-0A BRPI0509732A BRPI0509732A BR PI0509732 A BRPI0509732 A BR PI0509732A BR PI0509732 A BRPI0509732 A BR PI0509732A BR PI0509732 A BRPI0509732 A BR PI0509732A
Authority
BR
Brazil
Prior art keywords
prodrug
group
pharmaceutical composition
present
agent
Prior art date
Application number
BRPI0509732-0A
Other languages
English (en)
Inventor
Isao Umeda
Jun Ohwada
Sawako Ozawa
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of BRPI0509732A publication Critical patent/BRPI0509732A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

PRó-FáRMACO SOLúVEL EM áGUA, COMPOSIçãO FARMACêUTICA, AGENTE TERAPêUTICO, AGENTE ANTIFUNGO E USO DO REFERIDO PRó-FáRMACO. A presente invenção refere-se a um objetivo da presente invenção é de prover pró-fármacos solúveis em água que podem ser administrados parenteralmente e que mostram excelente solubilidade em água e pequenas inter-espécies ou diferenças individuais e são rapidamente convertidas na forma ativa por meio de conversão química. A presente invenção proporciono pró-fármacos solúveis em água representadas pela fórmula (1) ou sais farmaceuticamente aceitáveis ou hidratos ou solvatos das mesmas: em que: R¬ 1¬ representa um átomo de hidrogênio ou um grupo C~ 1~-C~ 6~ alquila; W representa um grupo divalente compreendendo um grupo amino terciário ou um grupo sulfonila; e Y representa um resíduo de um composto representado por Y-OH, compreendendo um grupo hidroxila alcoólico.
BRPI0509732-0A 2004-04-09 2005-04-08 pró-fármaco solúvel em água, composição farmacêutica, agente terapêutico, agente antifungo e uso do referido pró-fármaco BRPI0509732A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004115713 2004-04-09
PCT/JP2005/006957 WO2005097803A1 (ja) 2004-04-09 2005-04-08 新規水溶性プロドラッグ

Publications (1)

Publication Number Publication Date
BRPI0509732A true BRPI0509732A (pt) 2007-09-25

Family

ID=35124997

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509732-0A BRPI0509732A (pt) 2004-04-09 2005-04-08 pró-fármaco solúvel em água, composição farmacêutica, agente terapêutico, agente antifungo e uso do referido pró-fármaco

Country Status (18)

Country Link
US (1) US7910593B2 (pt)
EP (1) EP1757609B1 (pt)
JP (1) JP4823894B2 (pt)
KR (1) KR20070011457A (pt)
CN (1) CN1964979B (pt)
AU (1) AU2005230994A1 (pt)
BR (1) BRPI0509732A (pt)
CA (1) CA2563502A1 (pt)
HK (1) HK1100083A1 (pt)
IL (1) IL178465A0 (pt)
MX (1) MXPA06011679A (pt)
MY (1) MY145850A (pt)
NO (1) NO20065137L (pt)
NZ (1) NZ550665A (pt)
RU (1) RU2413731C2 (pt)
TW (1) TWI351284B (pt)
UA (1) UA88008C2 (pt)
WO (1) WO2005097803A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005514359A (ja) * 2001-11-23 2005-05-19 中外製薬株式会社 腫瘍を標的とする酵素の同定法
WO2004073601A2 (en) * 2003-02-21 2004-09-02 Chugai Seiyaku Kabushiki Kaisha Process for the preparation of hexacyclic camptothecin derivatives
US8652484B2 (en) 2004-02-13 2014-02-18 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US8435539B2 (en) * 2004-02-13 2013-05-07 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
WO2005097803A1 (ja) 2004-04-09 2005-10-20 Chugai Seiyaku Kabushiki Kaisha 新規水溶性プロドラッグ
TW200744603A (en) * 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
AU2006305169A1 (en) * 2005-10-19 2007-04-26 Chugai Seiyaku Kabushiki Kaisha Preventive or therapeutic agents for pancreatic cancer, ovarian cancer, or liver cancer comprising a novel water-soluble prodrug
PL2061749T3 (pl) * 2006-09-03 2018-11-30 Techfields Biochem Co. Ltd Dodatnio naładowane, rozpuszczalne w wodzie proleki acetaminofenu i związków pokrewnych o bardzo dużej szybkości przenikania przez skórę
WO2011072124A1 (en) * 2009-12-09 2011-06-16 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
CN104755482B (zh) * 2012-10-30 2017-04-26 内尔维阿诺医学科学有限公司 官能化的9‑溴‑喜树碱衍生物
JP7121722B2 (ja) 2016-04-04 2022-08-18 ケモセントリックス，インコーポレイティド 可溶性Ｃ５ａＲアンタゴニスト
JPWO2019059344A1 (ja) 2017-09-22 2020-11-26 大日本住友製薬株式会社 化学活性化型水溶性プロドラッグ
HUE060364T2 (hu) 2019-03-29 2023-02-28 Medimmune Ltd Vegyületek és konjugátumaik

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4473692A (en) 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
EP0220601B1 (en) 1985-10-21 1991-12-11 Daiichi Seiyaku Co., Ltd. Pyranoindolizine derivatives and preparation process thereof
US4981968A (en) 1987-03-31 1991-01-01 Research Triangle Institute Synthesis of camptothecin and analogs thereof
US4939255A (en) 1987-06-24 1990-07-03 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic camptothecin derivatives
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US4943579A (en) 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
JPH0271836A (ja) * 1988-09-05 1990-03-12 Agency Of Ind Science & Technol 繊維状極小分子集合体の製法
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
HU213136B (en) 1990-08-14 1997-02-28 Kyorin Seiyaku Kk Process for producing fluoroethyl camptothecin derivatives and pharmaceutical compositions containing them
JP3008226B2 (ja) 1991-01-16 2000-02-14 第一製薬株式会社 六環性化合物
ZA922180B (en) 1991-03-29 1993-09-27 Lilly Co Eli Piperidine derivatives
JP3359955B2 (ja) 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
US5840900A (en) * 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
GB9402934D0 (en) 1994-02-16 1994-04-06 Erba Carlo Spa Camptothecin derivatives and process for their preparation
US5663177A (en) 1995-05-31 1997-09-02 Smithkline Beecham Corporation Water soluble camptothecin analogs
JP2967184B2 (ja) * 1996-03-07 1999-10-25 工業技術院長 オリゴペプチド鎖のｃ端を両端にもつ双頭型脂質の製造方法
AU2406097A (en) 1996-04-26 1997-11-19 Daiichi Pharmaceutical Co., Ltd. Process for the preparation of tetrahydro-indolizines
AU739028B2 (en) 1996-09-27 2001-10-04 Bristol-Myers Squibb Company Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
UA57757C2 (uk) 1996-12-20 2003-07-15 Сос'Єте Де Консей Де Решерш Е Даплікасьон С'Єнтіфік (С.К.Р.А.С.) Аналоги камптотецину, спосіб їх отримання (варіанти) і фармацевтична композиція
EP1017675B1 (en) 1997-02-14 2006-06-14 Bionumerik Pharmaceuticals, Inc. Highly lipophilic camptothecin derivatives
US6294344B1 (en) 1997-03-19 2001-09-25 The Board Of Trustees Of The University Of Arkansas Methods for the early diagnosis of ovarian cancer
GB9709421D0 (en) 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
US6265540B1 (en) 1997-05-19 2001-07-24 The Johns Hopkins University School Of Medicine Tissue specific prodrug
US6326468B1 (en) 1997-06-13 2001-12-04 Gryphon Sciences Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution
GB9712370D0 (en) 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
GB9715821D0 (en) 1997-07-25 1997-10-01 Pharmacia & Upjohn Spa Amidino-camptothecin derivatives
DE69840216D1 (de) 1997-08-08 2008-12-24 Celmed Oncology Usa Inc Verfahren und Zubereitungen um Resistenz gegen biologische oder chemische Therapien zu Überwinden
JP4102466B2 (ja) 1997-11-14 2008-06-18 株式会社アミノアップ化学 抗癌剤の副作用軽減剤
US6130039A (en) 1997-12-12 2000-10-10 Incyte Pharmaceuticals, Inc. Polynucleotide encoding human lysyl hydroxylase-like protein
WO1999037753A1 (en) 1998-01-23 1999-07-29 Newbiotics, Inc. Enzyme catalyzed therapeutic agents
GB2334256A (en) 1998-02-12 1999-08-18 Univ Montfort Hydroxylation activated prodrugs
HU228314B1 (hu) 1998-09-04 2013-03-28 Millennium Pharmaceuticals Kemokin receptor antagonisták, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
BR0008524A (pt) 1999-02-27 2001-12-18 Boehringer Ingelheim Pharma Heterociclos bicìclicos, composiçõesfarmacêuticas que contêm esses compostos, seuuso e processos para a sua prerapação
AU4245500A (en) * 1999-04-15 2000-11-02 Regents Of The University Of California, The Protein transport assays
EE200100603A (et) 1999-05-14 2003-02-17 Imclone Systems Incorporated Inimese refraktaarsete kasvajate ravi epidermaalse kasvufaktori retseptori antagonistidega
AU7703400A (en) 1999-09-14 2001-04-17 Xenoport, Inc. Substrates and screening methods for transport proteins
US6268375B1 (en) 1999-12-29 2001-07-31 Research Triangle Institute 10, 11-difluoromethylenedioxycamptothecin compounds with topoisomerase I inhibition
YU64602A (sh) 2000-02-28 2005-06-10 Aventis Pharma S.A. Smeša koja se sastoji od kamptotecina i derivata pirimidina za terapiju kancera
EP1311266A2 (en) * 2000-06-28 2003-05-21 SuperGen, Inc. Combination hiv therapy including camptothecin
CA2416807A1 (en) * 2000-07-28 2002-02-07 Lion Bioscience Ag Regional intestinal permeability model
AU2002248229B2 (en) 2000-11-07 2006-11-30 Dana-Farber Cancer Institute, Inc. Method of treating hematologic tumors and cancers using beta lapachone
US6350756B1 (en) * 2001-01-18 2002-02-26 California Pacific Medical Center Camptothecin derivatives
US6803186B2 (en) * 2001-03-02 2004-10-12 The Iams Company Compositions and methods for increasing amino acid absorption in mammals
EP1406493A4 (en) * 2001-06-11 2006-06-14 Xenoport Inc ADMINISTRATION OF MEDIUM BY THE PEPT-2 TRANSPORTER
JP2005514359A (ja) 2001-11-23 2005-05-19 中外製薬株式会社 腫瘍を標的とする酵素の同定法
CN100338066C (zh) 2001-11-30 2007-09-19 中外制药株式会社 六环化合物
EP1572093B1 (en) * 2002-08-01 2013-04-17 Eisai Inc. Prevention of cancer with glutamine
PA8578001A1 (es) 2002-08-07 2004-05-07 Warner Lambert Co Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas
WO2004073601A2 (en) 2003-02-21 2004-09-02 Chugai Seiyaku Kabushiki Kaisha Process for the preparation of hexacyclic camptothecin derivatives
JP2005255643A (ja) 2004-03-15 2005-09-22 Masato Kusunoki 抗腫瘍効果増強方法および抗腫瘍効果増強剤
WO2005097803A1 (ja) 2004-04-09 2005-10-20 Chugai Seiyaku Kabushiki Kaisha 新規水溶性プロドラッグ
AU2005282761B2 (en) 2004-09-02 2012-02-02 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
TWI389897B (zh) 2005-02-22 2013-03-21 Chugai Pharmaceutical Co Ltd 1- (2H) -isoquinolinone derivatives
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
AU2006305169A1 (en) * 2005-10-19 2007-04-26 Chugai Seiyaku Kabushiki Kaisha Preventive or therapeutic agents for pancreatic cancer, ovarian cancer, or liver cancer comprising a novel water-soluble prodrug

Also Published As

Publication number Publication date
EP1757609A1 (en) 2007-02-28
HK1100083A1 (en) 2007-09-07
CN1964979B (zh) 2011-07-27
CN1964979A (zh) 2007-05-16
JPWO2005097803A1 (ja) 2008-02-28
CA2563502A1 (en) 2005-10-20
NO20065137L (no) 2006-12-21
IL178465A0 (en) 2007-02-11
RU2006139644A (ru) 2008-05-20
WO2005097803A1 (ja) 2005-10-20
US7910593B2 (en) 2011-03-22
NZ550665A (en) 2010-05-28
UA88008C2 (en) 2009-09-10
MY145850A (en) 2012-04-30
AU2005230994A1 (en) 2005-10-20
TWI351284B (en) 2011-11-01
US20080015157A1 (en) 2008-01-17
EP1757609B1 (en) 2013-10-16
RU2413731C2 (ru) 2011-03-10
JP4823894B2 (ja) 2011-11-24
TW200600088A (en) 2006-01-01
EP1757609A4 (en) 2010-09-01
MXPA06011679A (es) 2007-01-23
KR20070011457A (ko) 2007-01-24

Similar Documents

Publication Publication Date Title
BRPI0509732A (pt) pró-fármaco solúvel em água, composição farmacêutica, agente terapêutico, agente antifungo e uso do referido pró-fármaco
BRPI0715579A2 (pt) "composto, composição farmacêutica e uso de um composto"
MX2007005694A (es) Nuevos derivados de betulina, preparacion y uso de los mismos.
ECSP067110A (es) Derivados de 2-carbamida-4-feniltiazol, su preparación y su aplicación en terapéutica
RS51943B (en) PIPERIDINSKI GPCR AGONIST
WO2006025070A3 (en) Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol
UY30440A1 (es) Nuevos compuestos
ECSP066541A (es) Nuevos derivados de piridazin-3(2h)-ona
HRP20090162T1 (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
UY29169A1 (es) Derivados de 2-amido-4 feniltiazol, su preparacion y su aplicacion en terapeutica
DE60303961D1 (de) Modifizierte saccharide, deren konjugate sowie deren herstellung
DE602005016297D1 (de) Antithrombotische diamide
BRPI0518068A (pt) composto ou um éster ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, inibidor seletivo de aurora a, agente anti-tumor, e, preparação combinada
MY151295A (en) Pyrimidyl indoline compound
DE602005019316D1 (en) Aromatische etherderivate als thrombin-hemmer
BRPI0714885B8 (pt) compostos terapêuticos e seu uso
SG170049A1 (en) Novel 11 beta - hydroxyandrosta-4-ene-3-ones
WO2004082581A3 (fr) Application a titre de medicaments de derives de cholest-4-en-3- one, compositions pharmaceutiques les renfermant et nouveaux derives
UY30356A1 (es) Derivados de 3-halo-n-(2.(4-fluorofenil)-4-oxobutil)-n-metil-5-(trifluorometil)benzamida y composiciones de los mismos.
NO20060277L (no) Anvendelse av bisyklo [2.2.1] heptanderivater til fremstilling av nevrobeskyttende farmasoytiske sammensetninger
AR057555A1 (es) Un inhibidor de fosfodiesterasa-4 4-oxo-1-(3-sustituido fenil-1,4-dihidro-1,8-naftiridin-3-carboxamida y un procedimiento de preparacion del mismo
GEP20125392B (en) Tricyclic compounds and pharmaceutical use thereof
UY29817A1 (es) Nuevos compuestos de azetidina, composiciones farmacéuticas que los contienen, procesos de preparación y uso terapéutico de los mismos.
ATE308540T1 (de) Antithrombosemittel
NO20081587L (no) Aerosolformulering for inhalering

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2204 DE 02/04/2013.